IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
This study has been withdrawn prior to enrollment.
(The dose limiting toxicity of cardiac QTc prolongation was identified and demonstrated unsafe to continue clinical development of this molecule.)
Sponsor:
Astex Pharmaceuticals
Information provided by:
Astex Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01239108
First received: November 5, 2010
Last updated: September 6, 2012
Last verified: November 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Study Status: | This study has been withdrawn prior to enrollment. |
|---|---|
| Estimated Study Completion Date: | April 2012 |
| Estimated Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |